Of note, an ongoing randomized, phase 2 trial (NCT03968419) is evaluating the IL-1β inhibitor, canakinumab, or pembrolizumab, as monotherapy or in combination, as neoadjuvant therapy in patients with resectable NSCLC, with major pathological response (MPR) rate as the primary endpoint. The gene discussed is IL1B; the disease is non-small cell lung carcinoma.